Beijing InnoCare Pharma Tech Co., Ltd.
Registry sponsor category
Industry
- Other names
- Beijing InnoCare Pharma Tech Co., Ltd.
- Company name
- Beijing InnoCare Pharma Tech Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (59)
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
- A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
- A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects
- A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
- A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
- A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- A Study of ICP-022 in Patients With R/R DLBCL
- A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
- A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
- A Study of ICP-033 in Patients With Advanced Solid Tumors
- A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
- A Study of ICP-192 in Patients With Advanced Solid Tumors
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
- A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma
- A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
- A Study to Evaluate ICP-022 in Patients With CLL/ SLL